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Abstract
Introduction The objective of the present study was to
investigate the role of the stromal cell-derived factor 1 (SDF-1)/
CXCR4 axis in TNF-induced mobilization of osteoclast
precursors (OCPs) from bone marrow.
Methods OCPs were generated from bone marrow cells of
TNF-transgenic mice or wild-type mice treated with TNF or PBS.
The percentage of CD11b+/Gr-1-/lo OCPs was assessed by
fluorescence-activated cell sorting. OCP migration to the SDF-
1 gradient and the osteoclast forming potency were assessed in
chemotaxis/osteoclastogenic assays. SDF-1 expression was
assessed by real-time RT-PCR, ELISA and immunostaining in
primary bone marrow stromal cells, in the ST2 bone marrow
stromal cell line, and in bones from TNF-injected mice.
Results OCPs generated in vitro from wild-type mice migrated
to SDF-1 gradients and subsequently gave rise to osteoclasts in
response to RANKL and macrophage colony-stimulating factor.
TNF reduced SDF-1 expression by ST2 cells. Bone marrow
stromal cells from TNF-transgenic mice produced low levels of
SDF-1. TNF treatment of wild-type mice decreased the SDF-1
concentration in bone marrow extracts and decreased the SDF-
1 immunostaining of bone marrow stromal cells, and it also
increased the circulating OCP numbers. The percentage of
bone marrow CXCR4+ OCPs was similar in TNF-transgenic
mice and wild-type littermates and in TNF-treated and PBS-
treated wild-type mice.
Conclusion Systemically elevated TNF levels inhibit bone
marrow stromal cell production of SDF-1 and increase the
release of bone marrow OCPs to the peripheral blood.
Disruption of the SDF-1/CXCR4 axis by TNF may play an
important role in mediating OCP mobilization from the bone
marrow cavity in chronic inflammatory arthritis.
Introduction
TNF is a clinically validated etiological factor in inflammatory-
erosive arthritis and is known to synergize with RANKL and
macrophage colony-stimulating factor (M-CSF) to enhance
the differentiation of osteoclast precursors (OCPs) into bone-
resorbing osteoclasts in inflamed joints [1,2]. Patients with
psoriatic arthritis [3] and mice with TNF-induced arthritis [4,5]
have increased numbers of circulating OCPs, which correlate
with systemically increased TNF concentrations and are
reduced by anti-TNF therapy in association with clinical
improvement. These findings suggest that OCP mobilization
from the marrow may be involved in the pathogenesis of
inflammatory arthritis. The factors that mediate OCP mobiliza-
tion are currently unknown.
CKO = conditional knockout; ELISA = enzyme-linked immunosorbent assay; FACS = fluorescence-activated cell sorting; FITC = fluorescein isothi-
ocyanate; G-CSF = granulocyte colony-stimulating factor; IL = interleukin; M-CSF = macrophage colony-stimulating factor; NF = nuclear factor; 
OCPs = osteoclast precursors; PBS = phosphate-buffered saline PCR = polymerase chain reaction; RANKL = receptor activator of nuclear factor-
B ligand; RT = reverse transcriptase; SDF-1 = stromal cell-derived factor 1; Tg = transgenic; TGFβ = transforming growth factor beta; TNF = tumor 
necrosis factor.Arthritis Research & Therapy    Vol 10 No 2    Zhang et al.
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Stromal cell-derived factor 1 (SDF-1), a member of the C-X-C
chemokine family also known as CXCL12, acts through its
receptor CXCR4, and is the master chemokine that modulates
trafficking of hematopoietic stem cells and progenitors [6,7].
Studies of knockout mice reveal that the SDF-1/CXCR4 axis
is required for fetal B lymphopoiesis, bone marrow myelopoie-
sis and organogenesis [8-11]. Both SDF-1-deficient and
CXCR4-deficient mice die perinatally and have very few
hematopoietic stem cells and progenitors within their bone
marrow. SDF-1 and CXCR4 have been implicated in OCP
migration in vitro, and SDF-1 treatment of OCPs increases
osteoclastogenesis and subsequent osteoclast bone-resorb-
ing capacity [12,13].
SDF-1 is primarily produced by bone marrow stromal cells,
such as osteoblasts and endothelial cells [14]. Expression of
SDF-1 is controlled by various factors including hypoxia [15],
DNA damage [14] and cytokines, such as transforming growth
factor beta (TGFβ) [16] and granulocyte colony-stimulating
factor (G-CSF) [17]. G-CSF is used clinically to stimulate the
release of hematopoietic stem cells from the bone marrow into
the bloodstream of patients with a variety of malignancies. The
stem cells are then harvested from the blood as a source of
stem cells to be returned to patients following chemotherapy
or bone marrow transplantation. Whether or not inflammatory
cytokines such as TNF affect the SDF-1/CXCR4 axis in vivo
to control OCP mobilization, however, has not been studied.
We used TNF-transgenic (TNF-Tg) mice as a model of chronic
TNF overexpression and also injected WT mice with TNF as an
acute model to investigate the involvement of TNF in the SDF-
1/CXCR4 axis control of OCP mobilization. We found that
TNF directly inhibits SDF-1 production by bone marrow stro-
mal cells and that it has little effect on CXCR4 expression by
OCPs. A mechanism whereby TNF accelerates OCP mobiliza-
tion in inflammatory erosive arthritis may therefore be to reduce
bone marrow SDF-1 concentrations.
Materials and methods
Reagents and animals
Recombinant murine SDF-1, TNFα, and RANKL were from
R&D Systems (Minneapolis, MN, USA). Allophycocyanin–anti-
murine CD11b (M1/70) was from eBiosciences (San Diego,
CA, USA). FITC–anti-murine Gr-1 (RB6-8c5), biotin–anti-
CXCR4 (2B11/CXCR4) and streptavidin–PE-Texas Red con-
jugate were from BD PharMingen (San Diego, CA, USA).
Mouse SDF-1/CXCL12 DuoSet Development system was
from R&D Systems.
TNF-Tg mice in a CBA × C57BL/6 background (3647 TNF-
Tg line) were obtained originally from Dr G. Kollias and were
characterized by our group previously [4]. TNF-Tg mice have
been bred with C57/B6 mice for eight generations. Cxcr4
floxed and CD11b+/Cre mice were obtained from Dr YR Zou
[18] and Dr J Vacher [19], respectively. Both types of mice are
in a C57BL/6 background.
TNF was given by subcutaneous injection, as described previ-
ously [4]. The University Committee on Animal Resources of
the University of Rochester approved all studies.
Chemotaxis/osteoclastogenesis assay
Freshly isolated bone marrow cells were cultured with M-CSF
in  α-modified essential medium (Invitrogen, San Francisco,
CA, USA) supplemented with 10% fetal bovine serum (Invitro-
gen) for 3 days, and adherent cells were used as OCPs.
Assays were performed using transwell chemotaxis inserts
with 5-μm-pore polycarbonate filters (Corning Costar, Acton,
MA, USA). OCPs were labeled with Calcein AM (Molecular
Probes, Carlsbad, CA, USA) at a final concentration of 2 μg/
ml, and 100 μl (106 cells) cell suspension were loaded into the
upper chamber of a transwell insert. The transwell inserts were
immediately moved to wells of a 24-well tissue culture dish
containing different doses of SDF-1α (1, 10 or 100 ng/ml).
After 3 hours of incubation, the migrated cells in the bottom
wells were collected, centrifuged and solubilized (in 100 μl
Hank's Buffered Salt Solution with 1% SDS/0.2 N NaOH).
The calcein label was read in a 96-well FluoroNunc plate
(Nalge Nunc International, Rochester, NY, USA) and quanti-
fied in a Gemini XS microplate spectrofluorometer (Molecular
Devices, Sunnyvale, CA, USA) at 485 nm/530 nm.
The number of cells that migrated was calculated according to
a standard curve generated by plotting the calcein intensity of
serially diluted labeled cells versus the cell numbers. The per-
centage of migrated cells was calculated as follows: (migrated
cell number/total loaded cell number) × 100%. The cells in the
upper and lower chambers of the transwell were collected and
cultured with M-CSF and RANKL to determine whether they
could differentiate into osteoclasts, as described previously
[4]. These treated cells were fixed and stained for tartrate-
resistant acid phosphatase activity to identify osteoclasts. Tar-
trate-resistant acid phosphatase-positive cells containing ≥ 3
nuclei were counted as mature osteoclasts.
Fluorescence-activated cell sorting analysis
Bone marrow cells or peripheral blood were freshly isolated,
stained with various fluorescence-labeled antibodies, and sub-
jected to fluorescence-activated cell sorting (FACS) analysis,
as described previously [4,20].
Quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and cDNA was synthesized by the RNA
PCR Core Kit (Applied Biosystems, Branchburg, NJ, USA).
Quantitative PCR amplification was performed with gene-spe-
cific primers using an iCycler iQ Multiple-Color Real-Time
PCR Detection System (Bio-Rad Laboratories, Hercules, CA,
USA), as described previously [20].Available online http://arthritis-research.com/content/10/2/R37
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The primer sequences are as follows: SDF-1, forward 5'-
GCTCTGCATCAGTGACGG TA-3' and reverse 5'-TAAT-
TACGGGTCAATGCACA-3' ; CXCR4, forward 5'-CTTTGT-
CATCACACTCC-CCTT-3' and reverse 5'-
GCCCACATAGACTGCCT-TTTC-3' ; TGF-β, forward 5'-
TCACTGGAGTTGTACGGCAG-3' and reverse 5'-TCTCT-
GTGGAGCTGAAGCAA-3' ; G-CSF, forward 5'-GCTGCT-
GCTGT-GGCAAAGT-3' and reverse 5'-
AGCCTGACAGTGACCAGG-3' ; and actin, forward 5'-
ACCCAGATCATGTTTGAGAC-3' and reverse 5'-GTCAG-
GATCTTCATGA-GGTAGT-3'.
A relative standard curve method was used to calculate the
amplification efficiency. The standard curve was made from six
points corresponding to 10-fold cDNA dilution series. For
each sample, the relative amount was calculated from its
respective standard curve. Standards and samples were run in
triplicate.
Enzyme-linked immunosorbent assay
Culture supernatants were collected from primary stromal
cells and from the ST2 stromal cells. ELISA was performed
with the Mouse SDF-1/CXCL12 DuoSet Development sys-
tem. Ninety-six-well EIA/RIA plates (Costar, Corning, NY,
USA) were coated with a capturing monoclonal antibody to
SDF-1 and were then blocked with a mixture of 1% bovine
serum albumin, 0.05% NaN3 and 5% sucrose in PBS. Culture
supernatants were diluted in reagent diluent (1% bovine
serum albumin in PBS) and incubated for 2 hours at room tem-
perature. The detection antibody was diluted in reagent diluent
and incubated for 2 hours at room temperature. Antibody bind-
ing was detected with streptavidin-conjugated horseradish
peroxidase and developed with a substrate solution (1:1 mix-
ture of H2O2 and tetramethylbenzidine).
A standard curve was generated for each set of samples
assayed and was made from seven points of a twofold dilution
series. Each standard or sample was assayed in duplicate.
Preparation of bone sections and 
immunohistochemistry
Long bones from mice treated with TNF or PBS were fixed in
10% phosphate-buffered formalin, decalcified in 10% ethylen-
ediamine tetraacetic acid and embedded in paraffin wax.
Deparaffinized sections were quenched with 3% hydrogen
peroxide and were treated for antigen retrieval for 30 minutes.
Sections were then stained with a rabbit anti-SDF-1 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and immu-
nostaining was performed.
Generation of Cxcr4f/f/CD11b+/Cre conditional 
knockout mice
Cxcr4 floxed female mice were bred with CD11b+/Cre male
mice to generate the Cxcr4+/f/CD11b+/Cre F1 generation.
Cxcr4+/f/CD11b+/Cre  male mice were then crossed with
Cxcr4f/f female mice to produce Cxcr4f/f/CD11b+/Cre condi-
tional knockout mice (CXCR4 CKO). Each litter comprised
five to eight pups, indicating that deletion of CXCR4 in
CD11b+ cells does not cause embryonic death. CXCR4 CKO
mice were identified by PCR genotyping. The efficiency of
CXCR4 deletion in the bone marrow CD11b+  cells was
assessed by FACS analysis using FITC–anti-CD11b and allo-
phycocyanin–anti-CXCR4 antibodies.
Statistical analysis
All results are presented as the mean ± standard error of the
mean. Comparisons were made by analysis of variance and
Student's t test for unpaired data. P < 0.05 was considered to
represent statistical significance.
Results
SDF-1 has a chemotaxic effect on bone marrow OCPs
We and other workers have demonstrated that patients or
mice with chronic inflammatory arthritis have an increased fre-
quency of OCPs in peripheral blood and spleens, and that
TNF promotes the release of bone marrow OCPs into the
bloodstream [3-5]. To investigate whether the SDF-1/CXCR4
axis – the master chemokine system controlling mobilization of
hematopoietic stem cells and progenitors – mediates TNF-
induced OCP mobilization, we first verified that OCPs express
functional CXCR4 and migrate toward a SDF-1 gradient in a
combined chemotaxis/osteoclastogenesis assay. M-CSF-
dependent bone marrow mononuclear cells were generated in
vitro and were used as the source of OCPs. To confirm that
these cells are enriched for OCPs, we compared their surface
expression of CD11b and Gr-1 proteins, cell surface markers
for OCPs [20], with primary bone marrow mononuclear cells
isolated from the same mice.
As we reported previously [20], more than 10% of primary
bone marrow cells are CD11b+/Gr-1-/lo. After 3 days of culture
with M-CSF, more than 90% of adherent bone marrow cells
become CD11b+/Gr-1-/lo  – cells indicating enrichment of
OCPs (Figure 1a). We then demonstrated that these OCPs
migrated to SDF-1 gradients in a dose-dependent manner
(Figure 1b, left panel). The maximum chemotaxic response
was observed at 100 ng/ml SDF-1 and did not increase fur-
ther with up to 250 ng/ml SDF-1 (data not shown). No migra-
tion occurred when SDF-1 was included in both the upper and
lower chambers.
To confirm their osteoclast forming potency, we cultured the
OCPs that had migrated to the SDF-1 gradient with M-CSF
and RANKL, and demonstrated that they formed tartrate-
resistant acid phosphatase-positive osteoclasts (Figure 1b,
right panel). We also cultured nonmigrated OCPs from the
upper chamber with M-CSF and RANKL, and compared their
osteoclast forming potency with those that have migrated to
SDF-1 gradient (100 ng/ml) in the lower chamber. Both non-
migrated and migrated OCPs can give rise to matureArthritis Research & Therapy    Vol 10 No 2    Zhang et al.
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Figure 1
Effect of stromal cell-derived factor 1 on osteoclast precursor migration and differentiation Effect of stromal cell-derived factor 1 on osteoclast precursor migration and differentiation. (a) Wild-type bone marrow cells were cultured 
with PBS or macrophage colony-stimulating factor (M-CSF) for 3 days to generate osteoclast precursors (OCPs). Cells were stained with allophy-
cocyanin-labeled anti-CD11b and Phycoerythrin-labeled anti-Gr-1 antibodies and were subjected to fluorescence-activated cell sorting analysis. Dis-
tributions of CD11b+ and Gr-1-/lo cells are shown. Rectangle (CD11b+/Gr-1-/lo fraction), the majority of cells with osteoclast forming potency. (b) 
Wild-type OCPs were labeled with calcein AM and were seeded in the upper chamber of a transwell dish, and various amounts of stromal cell-
derived factor 1 (SDF-1) were added to the lower chamber. Percentage of migrated cells in the lower chamber determined by calcein intensity (left 
panel). Cells that migrated to the lower chamber were cultured with M-CSF and RANKL to form osteoclasts. Numbers of tartrate-resistant acid phos-
phatase-positive (TRAP+) cells per well was assessed (right panel). (c) OCPs were seeded in the upper chamber of a transwell with or without 100 
ng/ml SDF-1 in the lower chamber for 3 hours. Nonmigrated cells from the upper chamber and migrated cells from the lower chamber were cultured 
with M-CSF and RANKL to form osteoclasts. TRAP staining was formed. Bar graphs, numbers of TRAP+ cells/well (left panel). Representative pic-
tures show TRAP-stained osteoclasts formed from the lower chambers with or without SDF-1 (×10). (d) OCPs were cultured with M-CSF and 
RANKL plus SDF-1 (200 ng/ml) on bone slices for 9 days. Numbers of osteoclasts and resorption pits per slice were counted. Data are the mean ± 
standard error of the mean of four wells. Experiments were repeated three times with similar results. *P < 0.05 versus samples from PBS-treated 
cells.Available online http://arthritis-research.com/content/10/2/R37
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osteoclasts, but the cells from the lower chamber formed more
osteoclasts (Figure 1c, left panel). In contrast, cells that were
freely migrated to the lower chamber without a SDF-1 gradient
did not form osteoclasts under the same condition (Figure 1c,
right panel). These findings suggest that both nonmigrated
and SDF-1 migrated cells can differentiate into osteoclasts but
that CXCR4-positive cells have more osteoclast forming
potency.
To study the effect of SDF-1 on OCP differentiation and acti-
vation, OCPs were cultured with M-CSF and RANKL in the
presence or absence of SDF-1 (200 ng/ml) for 9 days on bone
slices. SDF-1 did not affect osteoclast numbers, but slightly
increased osteoclast resorptive activity (Figure 1d). SDF-1
had no effect on OCP production of TNF. In contrast, RANKL
significantly increased TNF expression under the same culture
conditions (fold induction of TNF over PBS: RANKL, 11.6 ±
0.9 versus SDF-1, 0.7 ± 0.1). The major role of SDF-1 in the
regulation OCPs therefore appears to affect their mobilization
through chemotaxis.
TNF reduces SDF-1 production by bone marrow stromal 
cells
Since an SDF-1 gradient determines the direction of mobiliza-
tion of hematopoietic stem cells and progenitors [6], we exam-
ined whether SDF-1 levels are decreased in bone marrow
stromal cells and long bone samples from TNF-Tg mice to
account for the increased OCP mobilization from their bone
marrow to their peripheral blood. SDF-1 mRNA and protein
levels were significantly reduced in the bone marrow stromal
cells (Figure 2a) and in the long bones from TNF-Tg mice com-
pared with wild-type littermates (Figure 2b).
To examine whether TNF directly affects SDF-1 production,
we treated ST2 cells – a bone marrow-derived cell line – with
TNF, and found that SDF-1 expression decreased within 8
hours and with a relatively low dose of TNF (0.1 ng/ml) (Figure
3a). TNF-reduced SDF-1 production was also confirmed at
protein levels (Figure 3a). Other osteoclastogenic cytokines,
including IL-1 and RANKL, had no effect on SDF-1 expression
(Figure 3b), while TGFβ significantly reduced SDF-1 mRNA
expression, as reported previously [16].
To determine whether the reduction in bone marrow expres-
sion of SDF-1 induced by TNF leads to OCP mobilization, we
treated wild-type mice with TNF using a subcutaneous injec-
tion protocol shown previously to increase the OCP frequency
in the blood [4,20]. As expected, TNF increased the blood
OCP numbers (Figure 4a). It also decreased SDF-1 protein
levels in bone marrow extracts (Figure 4b). The concentration
of SDF-1 in bone marrow was thus reduced significantly. Con-
sistent with the SDF-1 protein data, SDF-1 mRNA expression
was significantly decreased in the bone marrow cells of TNF-
treated mice (Figure 4c). As a control, TGFβ mRNA levels did
not change in the same samples (data not shown). Immunos-
taining with an anti-SDF-1 antibody showed that SDF-1 is
strongly expressed by osteoblasts on endosteal and trabecu-
lar bone surfaces of murine long bones (Figure 5, arrows). TNF
treatment was associated with loss of SDF-1-positive staining
Figure 2
Decreased stromal cell-derived factor-1 expression in bone marrow  stromal cells and bones of TNF-transgenic mice Decreased stromal cell-derived factor-1 expression in bone mar-
row stromal cells and bones of TNF-transgenic mice. (a) Bone mar-
row stromal cells from 6-month-old TNF-transgenic (TNF-Tg) mice and 
wild-type (WT) littermates were cultured in α-modified essential 
medium plus 20% fetal bovine serum for 7 days. The stromal cell-
derived factor 1 (SDF-1) protein concentration in the conditioned 
medium was assessed by ELISA (upper panel). Expression levels of 
SDF-1 mRNA were determined by real-time RT-PCR (lower panel). 
Fold changes were calculated using the value from WT mice as 1. (b) 
Long bones from the above mice were harvested and subjected to 
RNA extraction. Expression of SDF-1 was measured by real-time RT-
PCR. Data are the mean ± standard error of the mean of three load-
ings. The same results were obtained from three pairs of TNF-Tg mice 
and WT littermates. *P < 0.05 versus samples from WT littermates.Arthritis Research & Therapy    Vol 10 No 2    Zhang et al.
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Figure 3
TNF inhibits stromal cell-derived factor 1 expression by ST2 stromal  cells TNF inhibits stromal cell-derived factor 1 expression by ST2 stro-
mal cells. ST2 cells, a bone marrow stromal cell line, were treated with 
TNF or osteoclastogenic cytokines, and expression of stromal cell-
derived factor 1 (SDF-1) mRNA was determined by real-time RT-PCR. 
(a) Data from the cells treated with TNF (10 ng/ml) for various time 
points (upper panel) or different amounts of TNF for 24 hours (middle 
panel). Changes in SDF-1 protein levels in the conditioned medium 
were determined by ELISA 24 hours after TNF treatment (lower panel). 
(b) Data from the cells treated with osteoclastogenic cytokines for 24 
hours. Data are the mean ± standard error of the mean of three load-
ings. Data are representative of two independent experiments. *P < 
0.05 compared with PBS-treated cells. TGFβ, transforming growth fac-
tor beta.
Figure 4
TNF injection decreases bone marrow stromal cell-derived factor-1 lev- els and increases blood osteoclast precursor frequency TNF injection decreases bone marrow stromal cell-derived factor-
1 levels and increases blood osteoclast precursor frequency. Wild-
type mice (3/group) were given subcutaneous injections of murine TNF 
(0.5 μg/injection, 4 times/day) or PBS for 3 days and were sacrificed 2 
hours after the last injection on the fourth day. (a) The circulating 
CD11b+/Gr-1-/lo osteoclast precursor frequency was determined by flu-
orescence-activated cell sorting analysis. (b) Stromal cell-derived fac-
tor 1 (SDF-1) levels in the bone marrow were measured by ELISA. (c) 
Expression of SDF-1 mRNA in bone marrow was determined by real-
time RT-PCR. Data are the mean ± standard error of the mean of three 
pairs of mice receiving TNF or PBS injection. *P < 0.05 versus blood or 
PBS-treated mice.Available online http://arthritis-research.com/content/10/2/R37
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of these cells without affecting the cell morphology (Figure 5,
arrow heads), indicating that TNF inhibits SDF-1 production
by marrow osteoblasts.
TNF does not affect CXCR4 expression by osteoclast 
precursors
CXCR4 is the sole receptor for SDF-1, and CXCR4 knockout
mice die during embryonic development due to impaired cell
homing in the bone marrow [6]. To determine whether the
number of CXCR4+ cells is altered in TNF-Tg mice, the per-
centage of bone marrow CXCR4+/CD11b+/Gr-1-/lo OCPs
was examined by FACS analysis. No difference was observed
in the percentage of CXCR4+/CD11b+/Gr-1-/lo cells between
TNF-Tg mice and wild-type littermates (data not shown). TNF
pretreatment of wild-type OCPs in vitro had no effect on
CXCR4 expression on the cell surface (Figure 6a), and OCP
migration to SDF-1 gradients was similar between PBS-pre-
treated and TNF-pretreated cells (Figure 6b). TNF therefore
does not appear to influence the expression of CXCR4 by
OCPs.
To determine whether specific deletion of CXCR4 protein in
the OCPs affects TNF-induced OCP mobilization, we gener-
ated  Cxcr4f/f/CD11b+/Cre  conditional knockout (CXCR4
CKO) mice. FACS analysis of bone marrow CD11b+cells from
adult CXCR4 CKO mice indicate that more CD11b+ cells
from CXCR4 CKO mice are CXCR4-negative (49% in
CXCR4 CKO mice versus 22% in control mice; Figure 7b).
We administered TNF (0.5 μg/injection, 4/day for 3 days) to
CXCR4 CKO mice and their Cxcr4f/f/CD11b-/Cre  control
mice, and assessed the blood OCP frequency by FACS anal-
ysis. No clear difference in the percentage of CD11b+/Gr-1-/lo
OCPs between TNF-treated CXCR4 CKO mice and control
littermates was observed (Figure 7).
Discussion
Increased numbers of OCPs have been reported in the periph-
eral blood of mice in several animal models of arthritis [4,5]
and in patients with arthritis [3], but the mechanisms that medi-
ate this increase have not been elucidated. In the present
study, we investigated whether the SDF-1/CXCR4 axis is
involved in TNF-mediated OCP mobilization because this
chemokine system plays an essential role in hematopoietic
stem cell and progenitor homing [6]. We found that TNF
directly inhibits bone marrow stromal cell production of SDF-
1 and reduces SDF-1 levels in the bone marrow, which is
accompanied with an increase in the egress of OCPs from the
marrow. Decreased SDF-1 production by bone marrow
stromal cells in response to TNF overexpression may therefore
be one of the mechanisms mediating release of OCPs to the
peripheral blood in mice with TNF-induced arthritis or in
patients with inflammatory arthritis.
SDF-1-regulated cell mobilization is determined by local SDF-
1 gradients and/or CXCR4 expression on target cells.
Although alternation of either of these could lead to impaired
cell mobilization and homing, external factor regulation of SDF-
1 expression levels appears to be the major mechanism. For
example, hypoxia [15], DNA damage [14], proteases [21] and
cytokines – including TGFβ [16] and G-CSF [17] – all reduce
SDF-1 levels and stimulate hematopoietic stem cell release
from bone marrow. Regulation of CXCR4 expression by exter-
nal factors has been studied less and the results have been
inconsistent. This inconsistency may be related to small num-
bers of CXCR4-expressing cells and low expression levels by
these cells, making it difficult to reliably detect a change in the
number of CXCR4-positive cells.
Our findings that TNF significantly decreases SDF-1 levels but
has little effect on OCP CXCR4 expression suggest that, like
most hematopoietic cell mobilizers, TNF also promotes OCP
mobilization through regulation of SDF-1 rather than through
CXCR4 expression. TNF-mediated OCP mobilization, how-
ever, is different from stem cell and precursor mobilization
induced by SDF-1, G-CSF or other agents because TNF also
has a strong stimulatory effect on OCP generation. This
Figure 5
TNF injection decreases stromal cell-derived factor 1 expression by  bone marrow stromal cells TNF injection decreases stromal cell-derived factor 1 expression 
by bone marrow stromal cells. Expression of stromal cell-derived fac-
tor 1 (SDF-1) protein by bone marrow cells was examined by immunos-
taining with anti-SDF-1 antibody. Left panels: pictures taken at power 2 
to show the overall view of bone architecture. Right panels: pictures are 
the insert taken at power 20 to show SDF-1-positive bone marrow 
osteoblasts (upper panel arrows) in mice receiving PBS injection and 
to show SDF-1-negative cells (lower panel arrows) in TNF-injected 
mice. Photographs are representatives of one pair of TNF-injected or 
PBS-injected mice from three pairs of animals.Arthritis Research & Therapy    Vol 10 No 2    Zhang et al.
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represents a unique pathologic situation in chronic inflamma-
tory arthritis, in that the entire process of generation of OCPs
and their egress from the bone marrow is accelerated in
response to TNF. This situation leads to increased numbers of
OCPs in both bone marrow and blood, whereas SDF-1 or G-
CSF administration triggers a rapid release of cells from the
bone marrow – and the total bone marrow cell number is con-
sequently reduced.
We do not currently know the molecular mechanisms by which
TNF inhibits SDF-1 production. SDF-1 is regulated at both
transcriptional and post-translational levels [16,21]. We found
that TNF induced massive apoptosis of ST2 cells when a tran-
scription or translation inhibitor was used with TNF (data not
shown). In these circumstances it is therefore difficult to inves-
tigate the mechanism of action for TNF. Protease degradation
is one of the major mechanisms to reduce SDF-1 protein levels
[21], and protease release from neutrophils and other myeloid
cells can be stimulated by TNF. However TNF may also inhibit
SDF-1 expression at the RNA level within 8 hours of treatment
as shown by our data (Figure 3a).
TGFβ at concentrations as low as 0.01 ng/ml decreases SDF-
1 mRNA expression in stromal cells [16], implying that a small
change in TGFβ could alter SDF-1 concentrations. We found
that TNF increases TGFβ mRNA expression in ST2 cells. TNF
administration to wild-type mice had no effect on TGFβ
expression, however, although it significantly decreased SDF-
1 expression in bone marrow stromal cells. Therefore it is
unlikely that TGFβ mediates TNF-induced bone marrow SDF-
1 downregulation in vivo. G-CSF is another cytokine that
downregulates SDF-1 mRNA expression in osteoblasts [17].
TNF did not increase G-CSF in ST2 cells (data not shown),
however, suggesting that the reduction in SDF-1 induced by
TNF in vitro is not mediated by G-CSF. Furthermore, the SDF-
1 promoter does not contain binding sites typically present in
the other CXC chemokine promoters, especially for NF-κB,
interferon regulatory factor recognition elements or NF-IL6,
which are associated with transcriptional activation in
response to proinflammatory extracellular signals, such as
TNF, IL-6 or interferons [22]. These data suggest that studying
SDF-1 regulation may be more complicated than studying
other CXC chemokines.
Figure 6
TNF does not alter CXCR4 expression on osteoclast precursors TNF does not alter CXCR4 expression on osteoclast precursors. Wild-type bone marrow cells were cultured with macrophage colony-stimulat-
ing factor for 3 days and then treated with PBS or TNF (10 ng/ml) for 24 hours. (a) Cells were harvested and stained with Phycoerythrin-labeled 
anti-c-fms and FITC-labeled anti-CXCR4 antibodies and were subjected to fluorescence-activated cell sorting analysis. c-Fms-positive cells were 
gated and the cell surface expression level of CXCR4 is shown in the histogram. (b) Cells were subjected to a transwell assay where various 
amounts of stromal cell-derived factor 1 (SDF-1) were added in the lower chamber. After 3 hours of incubation, migrated cells in lower chamber 
were harvested and measured in a microplate spectrofluorometer. Percentage of migrated cells was determined as in Figure 1. Data are representa-
tive of two independent experiments.Available online http://arthritis-research.com/content/10/2/R37
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The present study did not provide a direct association
between TNF-reduced SDF-1 production and OCP mobiliza-
tion in vivo. We have attempted to answer this question using
mice with CXCR4 specifically deleted in OCPs by generating
CXCR4 CKO mice via crossing CXCR4 floxed mice [18] with
CD11b-Cre mice [19]. We injected TNF to these CXCR4
conditional mice to determine whether TNF-induced increased
OCP release is altered when CXCR4 expression has theoret-
ically been deleted in CD11b-expressing OCPs. Unfortu-
nately, we found that only about 50% of bone marrow CD11b+
cells have no CXCR4 surface expression in these CXCR4
CKO mice (Figure 7a), suggesting a low excision frequency of
the Cre recombinase in our system. With this leaky system, the
blood OCP frequency was similar between CXCR4 CKO
mice and wild-type mice (Figure 7b). Our results suggest that
CD11b-Cre mice appear not a good system to delete the
gene encoding cxcr4 in bone marrow CD11b-positive cells.
The importance of TNF-mediated reduction in SDF-1 produc-
tion in increased OCP mobilization in vivo needs to be further
confirmed using a model where SDF-1 concentration in the
bone marrow is maintained in the presence of TNF. Since
rheumatoid arthritis and other forms of inflammatory bone
disorders are chronic diseases, however, multiple factors may
contribute to promote OCP release from the bone marrow. For
example, we have demonstrated that TNF-stimulated OCP for-
mation could increase the OCP pool in bone marrow and push
cell egression [20]. Kindle and colleagues reported that TNF
activates endothelial cells and increases the attachment of
OCPs to vascular endothelium in vitro. They speculated that
this could increase the ability of OCPs to enter the blood-
stream [23]. It has been reported recently that RANKL-stimu-
lated osteoclastogenesis promotes the mobilization of
hematopoietic progenitor cells by cleaving SDF-1 through
bone-resorbing proteinase, cathepsin K [24]. TNF stimulates
osteoclastogenesis synergistically with RANKL [25], and this
mechanism may also apply to TNF-induced OCP mobilization.
The regulation of OCP mobilization is therefore a complicated
process, and decreased SDF-1 expression by bone marrow
stromal cells may represent another important mechanism.
Conclusion
Our findings demonstrate that TNF directly inhibits bone mar-
row stromal cells to produce SDF-1, which is associated with
increased release of OCPs from the bone marrow. The SDF1/
CXCR4 axis therefore may not only control hematopoietic cell
homing, but may also contribute to the accelerated OCP mobi-
lization in inflammatory arthritis where systemic TNF levels are
elevated.
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